February 9, 2022

European Clinical Trials Regulation is now applicable: Recent updates

This article has been also published on the EACCNY website on February 10, 2021.

On January 31, 2022, EU Regulation 536/2014 on clinical trials of medicinal products for human use (“Clinical Trials Regulation” or “CTR”) finally went into effect more than seven years after its approval, but Italy is not yet ready for its application.

This process has taken a long time (much longer than expected) due to the need to develop a complex IT architecture, i.e., a European portal for the management of clinical trials—the Clinical Trial Information System (CTIS)—to be used for all trial-related activity, from submission of an application for authorization through publication of trial results.

The CTR was designed to increase the competitiveness of research in Europe, where bureaucratic and administrative complexities related to the different procedures that must be implemented in each Member State to authorize a clinical trial often hamper competitiveness. Different Member State procedures with different timing and methods have created numerous difficulties for companies involved in multi-jurisdictional projects, and they often end up penalizing Europe as a whole and in particular the EU countries where authorization procedures are particularly slow and complex (a category in which Italy is often included).

The CTR therefore has the ambitious goal of bringing uniformity to the European Union. That is why it is being implemented via a regulation, which is directly applicable as approved in all Member States, instead of a directive, as was previously the case—a directive must be implemented by each Member State through its own law, creating an opportunity to introduce differences between countries.

A further (and even more ambitious) goal is to simplify and speed up these procedures. For this purpose, for example, a sponsor of a clinical trial will submit a single request for authorization to the portal, indicating the Member States where the trial will take place. A response (authorization or denial) will be provided for each. In addition, shorter authorization times (60 days) are expected. Should there be no decision within that timeframe, the trial may proceed (under “tacit authorization”).

Finally, the CTR also aims to achieve greater transparency throughout the process, from authorization to publication of results. In fact, the CTIS will be accessible to the public, with exceptions for information that requires confidentiality (e.g., personal data, confidential business information, and the like).

Next steps

Since the situation is still somewhat muddled at an operational level, operators will go through an introductory phase when there likely will be doubts and questions. With an eye to supporting operators during that time, the European Commission issued a Q&A document that was updated on February 1, 2022.

Certainly, operators will be helped by the fact that application of the CTR is not immediately compulsory. Instead, there will be a transition period of one year when applications for authorization of new trials can be submitted either through the CTIS or following the old procedure, at the discretion of the operator.

Within three years (January 31, 2025), however, ongoing trials will be transferred to the new system.

What is the situation in Italy?

Italy is still lagging in adapting its national system. Four years after the issuance of the Lorenzin Law No. 3/2018, which provided the adoption of a series of ministerial decrees designed in part to prepare the national system for application of the regulation, those decrees have yet to be issued. Therefore, there are many unresolved issues.

The main issue concerns the organization of ethics committees capable of dealing with requests for evaluation of trials on the very tight deadlines provided by the CTR.

The ethics committee reorganization plan calls for reducing their number to a maximum of 40 territorial ethics committees in addition to three national ethics committees. This reorganization will be essential for proper distribution of requests for authorization to be evaluated: the ethics committees are responsible for examining the ethical profiles of trials, including issues related to the informed consent of participants.

In late January, the Conference of Representatives of Government and Regions received the first draft of an implementing decree establishing ethics committees to be involved in assessment of clinical trials under the CTR, and the draft is currently under review.

In addition, AIFA recently published a note that provides operators guidance on managing this temporary phase, before finalization of the implementing decrees.

AIFA’s note on management of the temporary phase

On January 31, 2022, AIFA endorsed a proposal for the temporary management of trials started according to the CTR, pending the publication and full implementation of the ministerial decrees on the reorganization of ethics committees and single fee (“Note”).

The main aspects of the Note are as follows:

  • In this phase, it is possible to submit a partial application, relating only to Part I of the dossier, with related evaluation and approval of the clinical trial protocol and technical documents;
  • The ethics committee in charge of evaluating the trial as the national ethics committee may be chosen from among those centers not involved in the trial itself;
  • AIFA will publish on its website a list of existing ethics committees selected by the Regions willing to evaluate (on a voluntary basis) applications submitted through the CTIS;
  • Should the sponsor not indicate a national ethics committee to use, AIFA shall choose an ethics committee for the trial by means of an algorithm that allows adequate rotation;
  • Sponsors must pay a single fee at the national level for clinical trial applications: If only Part I of the dossier is submitted, a sponsor can either (i) pay the first installment of the fee, based on the current rates in force for applications submitted to AIFA; or (ii) pay the full ethics committee fee and AIFA will then transfer the remainder of the related fee;
  • Once the ministerial decrees are published and the ethics committees fully activated, for all subsequent activities, trials evaluated according to the transitional modality automatically will be transferred to the appropriate ethics committee within the same Region, which will replace the committee acting voluntarily.


Draft decree on the involvement of ethics committees in clinical trial evaluation

As mentioned above, a draft decree on the involvement of ethics committees in clinical trial evaluation is currently under review by the Conference of Representatives of Government and Regions.

According to the draft decree, the ethics committee assigned to evaluate Part II of a clinical trial dossier must be selected from the 40 committees included on the list attached to the decree (that list is currently empty).

Additionally: (i) Regions are free to choose whether to maintain existing ethics committees not included on the list attached to the decree until the reorganization under the Lorenzin Law takes effect; and (ii) if Regions intend to maintain existing ethics committees, those committees are not to be involved in assessment of clinical trials pursuant to the CTR.

Following publication of this decree in the Italian Official Gazette, the Regions will be required to appoint the members of the 40 ethics committees. The deadline for the Regions to appoint members is not provided in the draft decree, but it will be included in the final version. Once the deadline for appointment of members of the committees has passed, the decree will be applicable.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on